Trial · NCT02737475
Adverse events10,287
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 10,287Pages stop at row 10,000
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Escalation Part 1: BMS 20 mg Q2W | 0 | 4 | |
| other | Anaemia | Blood and lymphatic system disorders | Escalation Part 1: BMS 40 mg Q2W | 1 | 4 | |
| other | Anaemia | Blood and lymphatic system disorders | Escalation Part 1: BMS 80 mg Q2W | 2 | 4 | |
| other | Anaemia | Blood and lymphatic system disorders | Escalation Part 1: BMS 160 mg Q2W | 0 | 4 | |
| other | Anaemia | Blood and lymphatic system disorders | Escalation Part 1: BMS 320 mg Q2W | 0 | 4 | |
| other | Anaemia | Blood and lymphatic system disorders | Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | 3 | 7 | |
| other | Anaemia | Blood and lymphatic system disorders | Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | 4 | 8 | |
| other | Anaemia | Blood and lymphatic system disorders | Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | 2 | 12 | |
| other | Anaemia | Blood and lymphatic system disorders | Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | 1 | 8 | |
| other | Anaemia | Blood and lymphatic system disorders | Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | 1 | 8 | |
| other | Anaemia | Blood and lymphatic system disorders | Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | 0 | 4 | |
| other | Anaemia | Blood and lymphatic system disorders | Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | 3 | 10 | |
| other | Anaemia | Blood and lymphatic system disorders | Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | 2 | 7 | |
| other | Anaemia | Blood and lymphatic system disorders | Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | 3 | 8 | |
| other | Anaemia | Blood and lymphatic system disorders | Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | 2 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | 8 | 18 | |
| other | Anaemia | Blood and lymphatic system disorders | Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | 5 | 12 | |
| other | Anaemia | Blood and lymphatic system disorders | Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | 2 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | 2 | 7 | |
| other | Anaemia | Blood and lymphatic system disorders | Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | 0 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02737475/events